The low-energy excesses observed by the MiniBooNE experiment have, to date, defied a convincing explanation under the standard model even with accommodation for nonzero neutrino mass. In this paper ...we explore a new oscillation mechanism to explain these anomalies, invoking a light neutrinophilic Higgs boson, conceived to induce a low Dirac neutrino mass in accord with experimental limits. Beam neutrinos forward scattering off of a locally overdense relic neutrino background give rise to a novel matter effect with an energy-specific resonance. An enhanced oscillation around this resonance peak produces flavor transitions which are highly consistent with the MiniBooNE neutrino- and antineutrino-mode data sets. The model provides substantially improved χ2 values beyond either the no-oscillation hypothesis or the more commonly explored 3+1 sterile neutrino hypothesis. This mechanism would introduce distinctive signatures at each baseline in the upcoming short-baseline neutrino program at Fermilab, presenting opportunities for further exploration.
The ArgoNeuT Collaboration presents the first measurements of inclusive muon neutrino charged current differential cross sections on argon. Obtained in the NuMI neutrino beam line at Fermilab, the ...flux-integrated results are reported in terms of outgoing muon angle and momentum. The data are consistent with the Monte Carlo expectation across the full range of kinematics sampled, 0°<θ(μ)<36° and 0<P(μ)<25 GeV/c. Along with confirming the viability of liquid argon time projection chamber technology for neutrino detection, the measurements allow tests of low-energy neutrino scattering models important for interpreting results from long baseline neutrino oscillation experiments designed to investigate CP violation and the orientation of the neutrino mass hierarchy.
The presence of skeletal metastases in patients suffering from cancer leads to a variety of clinical complications. Bisphosphonates are a class of drugs with a potent bone resorption inhibition ...activity that have found increasing utility in treating and managing patients with metastatic bone disease. Several clinical trials have demonstrated that bisphosphonates have clinical value in the treatment and management of skeletal metastases derived from advanced prostate cancer. Currently, the mechanism(s) through which bisphosphonates exert their activity is only beginning to be understood. We have studied the effects of bisphosphonate treatment on the growth of prostate cancer cell lines in vitro. Treatment of PC3, DU145, and LNCaP cells with pamidronate or zoledronate significantly reduced the growth of all three cell lines. Using flow cytometry, pamidronate treatment (100 microM) was shown to induce significant amounts of cell death in all three cell lines studied. In contrast, treatment with zoledronate (100 microM) did not induce cell death, instead exerting dramatic effects on cell proliferation, as evidenced by a major increase in cells present in the G0-G1 and S phase. Although both drugs reduced prostate cancer cell growth in the presence of serum, zoledronate was more potent under these conditions, disrupting growth at doses as low as 25 microM in the presence of 5% fetal bovine serum. These results raise the intriguing possibility that the observed clinical utility of bisphosphonates in managing skeletal metastases may in part derive from direct inhibition of prostate cancer cell growth in the bone microenvironment.
PDF
